The FDA has approved Zeposia 0.92 mg for the treatment of moderate-to-severe ulcerative colitis.

Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved for moderate-to-severe active UC, may reduce the lymphocyte migration into the intestines, according to the press release.

The approval is based on results from True North, a phase 3 trial that assessed ozanimod as an induction and maintenance therapy compared with placebo in patients with moderate-to-severe active UC (ozanimod n=429 vs. placebo n=216).

“In True North, Zeposia

Full Article: